| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
|
Nat Genet
|
2013
|
3.81
|
|
2
|
Genome-wide association analysis identifies three new breast cancer susceptibility loci.
|
Nat Genet
|
2012
|
3.20
|
|
3
|
Relationship between age and axillary lymph node involvement in women with breast cancer.
|
J Clin Oncol
|
2009
|
2.27
|
|
4
|
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
|
Clin Cancer Res
|
2011
|
2.09
|
|
5
|
Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial.
|
BMJ
|
2011
|
1.60
|
|
6
|
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
|
J Clin Oncol
|
2012
|
1.29
|
|
7
|
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
|
Breast Cancer Res Treat
|
2006
|
1.26
|
|
8
|
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.23
|
|
9
|
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
|
J Clin Oncol
|
2008
|
1.17
|
|
10
|
Management of borderline ovarian neoplasms.
|
J Clin Oncol
|
2007
|
1.15
|
|
11
|
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
|
Eur Radiol
|
2013
|
1.09
|
|
12
|
Chemotherapy for recurrent cervical cancer.
|
Gynecol Oncol
|
2007
|
1.03
|
|
13
|
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium.
|
Hum Mol Genet
|
2013
|
1.00
|
|
14
|
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
|
Eur J Cancer
|
2012
|
0.99
|
|
15
|
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
|
J Clin Oncol
|
2010
|
0.98
|
|
16
|
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
|
Breast Cancer Res Treat
|
2008
|
0.97
|
|
17
|
Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
|
Gynecol Oncol
|
2012
|
0.95
|
|
18
|
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
|
Breast Cancer Res Treat
|
2008
|
0.94
|
|
19
|
Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: first report on the technique used in 5 patients.
|
Acta Obstet Gynecol Scand
|
2008
|
0.92
|
|
20
|
Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors.
|
Int J Cancer
|
2014
|
0.90
|
|
21
|
The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
|
Gynecol Oncol
|
2007
|
0.90
|
|
22
|
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
|
Oncologist
|
2008
|
0.89
|
|
23
|
Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?
|
Gynecol Oncol
|
2012
|
0.89
|
|
24
|
Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.
|
Gynecol Oncol
|
2012
|
0.87
|
|
25
|
Evolution in endometrial cancer: evidence from an immunohistochemical study.
|
Int J Gynecol Cancer
|
2011
|
0.87
|
|
26
|
The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.
|
Int J Gynecol Cancer
|
2011
|
0.85
|
|
27
|
Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
|
Int J Gynecol Cancer
|
2009
|
0.84
|
|
28
|
Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology.
|
Int J Gynecol Cancer
|
2012
|
0.81
|
|
29
|
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
|
Int J Gynecol Cancer
|
2014
|
0.79
|
|
30
|
The management of borderline tumours of the ovary.
|
Curr Opin Oncol
|
2006
|
0.79
|
|
31
|
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
|
Adv Ther
|
2015
|
0.79
|
|
32
|
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
|
J Clin Oncol
|
2008
|
0.79
|
|
33
|
Genetic changes in nonepithelial ovarian cancer.
|
Expert Rev Anticancer Ther
|
2013
|
0.78
|
|
34
|
Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?
|
Gynecol Oncol
|
2010
|
0.78
|
|
35
|
The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2010
|
0.77
|
|
36
|
Pelvic exenterations for gynecological malignancies: a study of 36 cases.
|
Int J Gynecol Cancer
|
2012
|
0.77
|
|
37
|
The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
|
Gynecol Oncol
|
2010
|
0.76
|
|
38
|
Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
|
Eur J Cancer
|
2012
|
0.76
|
|
39
|
The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
|
Gynecol Oncol
|
2012
|
0.75
|
|
40
|
Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience.
|
Int J Gynecol Cancer
|
2015
|
0.75
|
|
41
|
Multi-center experience of robot-assisted laparoscopic para-aortic lymphadenectomy for staging of locally advanced cervical carcinoma.
|
Acta Obstet Gynecol Scand
|
2013
|
0.75
|
|
42
|
EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
|
Int J Gynecol Cancer
|
2012
|
0.75
|
|
43
|
Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors.
|
Gynecol Obstet Invest
|
2017
|
0.75
|
|
44
|
Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients.
|
Eur J Cancer
|
2010
|
0.75
|
|
45
|
Supervised classification of array CGH data with HMM-based feature selection.
|
Pac Symp Biocomput
|
2009
|
0.75
|
|
46
|
Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
47
|
Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
48
|
Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I-II Cervical Cancer.
|
Int J Gynecol Cancer
|
2017
|
0.75
|